Skip navigation

“The first half of 2016 has seen significant advances across all levels of the organization — we have begun to recognize revenues associated with our Canadian commercial efforts, in-licensed two branded epilepsy products for Canada, and continued to advance our internal product pipeline including the completion of a Proof of Concept clinical study for our transdermal aripiprazole program. We have also completed formulation work on our transdermal epilepsy and transdermal anti-nausea programs and are encouraged by the drug levels we are achieving in our experiments and animal models. We expect both programs to be transferred to our manufacturing partner this fall and look forward to continued advancements from all three internal programs going forward,” said Doug Janzen, Chairman and CEO of Aequus. “For our commercial arm, the first half of this year has largely been about laying the foundation for growth, both organizationally and for the portfolio,” said Ian Ball, Chief Commercial Officer at Aequus. “We have taken significant steps in market access, achieving private reimbursement for our ophthalmology program and progressing as planned for public reimbursement in major provinces. For our transplant program, we have continued to build physician support by communicating the strong clinical package that forms the bedrock of our switch program and ultimately driving cost savings for patients and payors.” Commercial Business Update: Second-quarter 2016 revenues of $118,100 was driven by the strong execution of our initial promotional efforts on Tacrolimus IR and launch stock-in of Vistitan during the quarter. Aequus’ sales and marketing strategy for its partners is anchored around its in-depth understanding of how to effectively navigate the public and private payor environment. Public listings drive the majority of product utilization in Canada, and requires targeted submissions and negotiations with individual provinces. For specialty products, such as tacrolimus, group purchasing organizations (“GPOs”) drive hospital formulary decisions, and are key in the successful adoption of the product. no dataTacrolimus IR: On December 2nd, 2015, Aequus initiated promotional activities for Tacrolimus IR, a first to market specialty generic used for the prevention of organ rejection in transplant. To date, Aequus has achieved key GPO successes in Ontario and Quebec, driving hospital uptake in those two major provinces.

For the original version including any supplementary images or video, visit

A chalazion looks like a sty, but mostly grows away from the edge of the eyelid. This condition may lead to blindness in the long ladder. In Dogs: The unique feature of the canine disease is that, for some unknown reason, it affects their left eye first. Shingles or herpes Foster as it is alternately labelled, cannot be cured but there are medications to help with the pain and the complications of the condition if left untreated. This is because the inflamed sinuses bring tremendous pressure on these body parts, including the eye. Alpha agonises, Prostaglandin analogy are other medications that also carry out the same function. It is essential to follow certain self-help methods to ease the discomfort caused due to strain. Slight change in the production, or drainage of aqueous humour can affect GOP significantly.

Examining Major Aspects Of Glaucoma

If these medications prove ineffective, doctors advise surgery. Dilation of small arteries or blood vessels due to use of these drugs may also have an effect on blood pressure. Extensive medical research is being carried out to find out the most effective cure for this eye disease. This article provides some information on the same that might prove beneficial. There is a common misconception that this is not possible. The veterinary ophthalmologist will frequently monitor the intra ocular pressure and evaluate the drainage pathway. Optic nerve, also known as cranial nerve, is a part of the central nervous system. This article discusses the causes, symptoms, and treatment options for the same. ——————————————————————————– Jim Molloy, Laidlaw & Co. | New Scarlett Burns

To read more about keyword visit

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>